Benjamin R Clopper

Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024

Heidi L. Moline, Ayzsa Tannis, Ariana P. Toepfer et al. · MMWR Morbidity and Mortality Weekly Report · 2024 · 202 citations · Full text

Veterinary Medicine, Infectious Diseases, Pediatrics +17

Respiratory Virus Surveillance Among Children with Acute Respiratory Illnesses — New Vaccine Surveillance Network, United States, 2016–2021

Ariana Perez, Joana Y Lively, Aaron T. Curns et al. · MMWR Morbidity and Mortality Weekly Report · 2022 · 138 citations · Full text

Veterinary Medicine, Infectious Diseases, Pediatrics +17

Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States

Aaron M. Frutos, Ashley M. Price, Elizabeth Harker et al. · MMWR Morbidity and Mortality Weekly Report · 2024 · 86 citations · Full text

Medicine, Infectious Diseases, Pediatrics +17

<i>Notes from the Field:</i>Reemergence of<i>Mycoplasma pneumoniae</i>Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018–2024

Chris Edens, Benjamin R Clopper, Jourdan DeVies et al. · MMWR Morbidity and Mortality Weekly Report · 2024 · 75 citations · Full text

Veterinary Medicine, Infectious Diseases, Pediatrics +12

Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024

Heidi L. Moline, Ariana P. Toepfer, Ayzsa Tannis et al. · JAMA Pediatrics · 2024 · 61 citations · Full text

Public Health, Infectious Diseases, Pediatrics +17